Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Comorbidities common among patients with COPD

Comorbidities are common among patients with chronic obstructive pulmonary disease (COPD), and a number of these comorbidities are independently associated with an increased mortality risk, according to a new study.

4 May 2012

TGA approves Ikaria’s LUCASSIN to treat Hepatorenal Syndrome Type 1

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, announced today the approval of LUCASSIN (terlipressin) by the Therapeutic Goods Administration (TGA) of Australia.

24 Apr 2012

EMA CHMP recommends approval of AMAG’s ferumoxytol

AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

21 Apr 2012

Fish oil not as beneficial for the heart as thought: Study

Fish oil, a combination of omega-3 fatty acids that has attracted much research on its effects on heart health. So far, the evidence has been inconclusive -- some studies have found fish oil has been major in preventing heart attacks, strokes and sudden cardiac death, while others have found fish oil has no benefits at all.

10 Apr 2012

RegeneRx wins four patents in Israel, Mexico

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel.

10 Apr 2012

Merck announces data from ZOSTAVAX Phase III study on shingles

Merck, known as MSD outside the United States and Canada, announced today that data from the pivotal Phase III study with ZOSTAVAX(Zoster Vaccine Live) in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases.

3 Apr 2012

Paying doctors and hospitals for better outcomes may not pay off

Medicare's largest effort to pay bonuses to hospitals that hit key performance measures -- or dock them if they miss -- did not lead to fewer deaths for heart attacks and heart bypass surgery, a new study finds. The analysis could lead to a reexamination of the idea of paying providers based on quality metrics, rather than on volume, which is key to the health law.

30 Mar 2012

Higher spending on effective procedures and services leads to better patient outcomes

Among hospitals in Ontario, Canada, those with higher levels of spending, which included higher intensity nursing and greater use of specialists and procedures, had an associated lower rate of deaths, hospital readmissions, and better quality of care for severely ill hospitalized patients, according to a study in the March 14 issue of JAMA.

14 Mar 2012

Scientists track genetic pathway of prostate cancer in new approach to drug discovery

Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.

14 Mar 2012

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

8 Mar 2012

Positive reaction from hospitals, consumer groups on 'stage 2' health IT rules

Both hospital and consumer groups are reacting positively to new federal rules meant to improve the effective use of the technology, and new electronic health records certification rules are released.

29 Feb 2012

Enrollment complete in Ikaria iNO Pivotal Phase III trial for BPD

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).

27 Feb 2012

ATI commences European trial of neurostimulation system for migraine

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable stimulator for severe headaches, today announced initiation of a study in Europe to evaluate the safety and efficacy of the company's investigational neurostimulation system for the treatment of high frequency, high disability migraine.

27 Feb 2012

Apixio introduces Clinical Knowledge Exchange at HIMSS 2012 conference

Apixio, Inc., the leading provider of clinical data integration, search and analytics for healthcare organizations, is introducing this week at the HIMSS 2012 conference, a technology framework called the Clinical Knowledge Exchange.

20 Feb 2012

University of Georgia researcher to develop first Chagas vaccine for pets

Chagas disease is the single most common cause of congestive heart failure and sudden death in the world. The devastating parasitic infection affects millions of people throughout Central and South America. But as global travel increases, it's becoming a greater threat in the United States and Europe as well.

17 Feb 2012

Controversy over psychiatric diagnosis reaches a fever pitch

As the Diagnostic and Statistical Manual of Mental Disorders is revised for the first time since 1994, controversy about psychiatric diagnosis is reaching a fever pitch.

16 Feb 2012

TKR surgeries have more than doubled over the past decade

New research presented at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that more than 4.5 million Americans are living with a total knee replacement (TKR), as the number of TKR surgeries has more than doubled over the past decade, with the sharpest rise among younger patients. Osteoarthritis continues to be the primary reason for TKR.

10 Feb 2012

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Study highlights benefits of TKR in elderly patients with osteoarthritis

New research presented at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) highlights the benefits of total knee replacement (TKR) in elderly patients with osteoarthritis, including a lower probability of heart failure and mortality.

7 Feb 2012

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA (sitagliptin), with extended-release metformin.

3 Feb 2012